MON-567 - Mid_Pregnancy Serum Ferritin Levels Are Not Associated with Korean Women C Gestational Diabetes Mellitus

Elevated serum ferritin levels (often >60-90 ng/mL) in pregnancy are associated with an increased risk of developing Gestational Diabetes Mellitus (GDM), potentially due to increased insulin resistance, inflammation, and oxidative stress.

A retrospective study examined women with singleton pregnancies at 24-28 weeks of gestation from December 2025 until January 2026 in Dongtan Jeil Women’s Hospital, Korea. We sampled 1-hour 50 g oral glucose tolerance test, Hb, and ferritin, Women over 50 g GTT were stratified by 75 g GTT. 55 participants with complete data on serum ferritin levels and gestational diabetes mellitus (GDM) status were included in the final analysis.

Women who developed GDM tended to have a higher pre-pregnancy body mass index compared with those without GDM. Age showed an inverse association with GDM occurrence in this cohort. When serum ferritin levels were categorized into quartiles, no increased risk of GDM was observed in higher ferritin quartiles. In particular, women in the highest ferritin quartile did not show a higher odds of GDM compared with those in the lowest quartile after adjustment for age and pre-pregnancy BMI (adjusted p = 0.28). Cutoff-based analyses using ferritin thresholds of 60 ng/mL and 80 ng/mL also demonstrated no significant association between elevated ferritin levels and GDM development. In multivariable logistic regression models adjusting for age, pre-pregnancy BMI, and HOMA-IR, serum ferritin levels were not independently associated with GDM (p = 0.72). No significant interaction was observed between ferritin and pre-pregnancy BMI or between ferritin and insulin resistance indices.
Correlation analyses showed weak positive correlations between serum ferritin and HOMA-IR (ρ = 0.22), fasting insulin (ρ = 0.22), and C-peptide levels (ρ = 0.25), indicating limited metabolic relevance.

Overall, mid-pregnancy serum ferritin levels were not associated with the development of gestational diabetes in Korean women.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*